| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/25/2013 | WO2013109421A1 Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles |
| 07/25/2013 | WO2013109354A2 Etravirine formulations and uses thereof |
| 07/25/2013 | WO2013109316A1 Enteric-coated ht-2157 compositions and methods of their use |
| 07/25/2013 | WO2013109230A1 Pharmaceutical compositions comprising tadalafil |
| 07/25/2013 | WO2013109229A1 Tablet formulations comprising cefixime as active agent |
| 07/25/2013 | WO2013109228A1 Formulations comprising cefixime as active agent |
| 07/25/2013 | WO2013109227A1 Pharmaceutical compositions comprising ceftibuten |
| 07/25/2013 | WO2013109226A1 Pharmaceutical tablet formulations comprising cefuroxime |
| 07/25/2013 | WO2013109225A1 Pharmaceutical tablet formulations comprising ceftibuten |
| 07/25/2013 | WO2013109224A1 Pharmaceutical compositions comprising diclofenac |
| 07/25/2013 | WO2013109223A1 Particulate formulations of tadalafil in effervescent form |
| 07/25/2013 | WO2013109222A1 Formulations comprising diclofenac as the active agent |
| 07/25/2013 | WO2013109221A1 New effervescent formulations comprising sweetener composition |
| 07/25/2013 | WO2013109220A1 Dry powder formulations comprising tiotropium, formoterol and budesonide |
| 07/25/2013 | WO2013109219A1 Dry powder formulations comprising tiotropium and carmoterol |
| 07/25/2013 | WO2013109218A1 Dry powder formulations comprising carmoterol and ciclesonide |
| 07/25/2013 | WO2013109217A1 Pharmaceutical formulations comprising aztreonam |
| 07/25/2013 | WO2013109215A1 Preparation of dry powder formulations comprising formoterol |
| 07/25/2013 | WO2013109214A1 Process for the preparation of dry powder formulations |
| 07/25/2013 | WO2013109213A2 Pharmaceutical formulations comprising tiotropium |
| 07/25/2013 | WO2013109212A1 Dry powder formulations comprising ciclesonide |
| 07/25/2013 | WO2013109211A1 Dry powder formulations comprising r-formoterol as active agent |
| 07/25/2013 | WO2013109210A1 Dry powder formulations comprising budesonide |
| 07/25/2013 | WO2013109209A1 Dry powder formulations comprising fluticasone |
| 07/25/2013 | WO2013109208A1 Formulations comprising formoterol as active agent |
| 07/25/2013 | WO2013109207A1 Dry powder formulations comprising mometasone |
| 07/25/2013 | WO2013109206A1 Tablet formulations comprising cefuroxime |
| 07/25/2013 | WO2013109205A1 Pharmaceutical tablet formulations comprising cefetamet |
| 07/25/2013 | WO2013109204A1 Compositions comprising cefditoren pivoxil |
| 07/25/2013 | WO2013109203A1 Tablet formulations comprising cefditoren pivoxil |
| 07/25/2013 | WO2013109201A1 Pharmaceutical compositions comprising cefprozil and clavulanic acid |
| 07/25/2013 | WO2013109199A1 Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12 |
| 07/25/2013 | WO2013109057A1 Magnetic nanoparticle-samirna complex and method for preparing same |
| 07/25/2013 | WO2013108991A1 Biocompatible particles and method for preparing same |
| 07/25/2013 | WO2013108270A1 Curcumin coated magnetite nanoparticles for biomedical applications |
| 07/25/2013 | WO2013108254A1 Formulation and method for increasing oral bioavailability of drugs |
| 07/25/2013 | WO2013108180A1 Aqueous paracetamol composition for injection |
| 07/25/2013 | WO2013107909A1 Lattice loss reduction |
| 07/25/2013 | WO2013107839A2 Phospholipid compounds for use in skin cancer treatment |
| 07/25/2013 | WO2013107810A1 Transmucosal administration system for a pharmaceutical drug |
| 07/25/2013 | WO2013107770A1 Sanitary device for applying an active principle within a body cavity |
| 07/25/2013 | WO2013107609A1 Systemic administration forms with controlled release and improved stability |
| 07/25/2013 | WO2013107515A1 Eye drop composition |
| 07/25/2013 | WO2013107503A1 Method for producing cinacalcet compositions for direct tableting |
| 07/25/2013 | WO2013107443A1 Method and applicator for the perioperative disinfection of medical instruments to be inserted through non-natural openings |
| 07/25/2013 | WO2013107441A1 Process for producing a solid pharmaceutical composition comprising the active ingredient rasagiline |
| 07/25/2013 | WO2013107427A1 Therapeutic compositions for intranasal administration of zolpidem |
| 07/25/2013 | WO2013107206A1 Chinese herbal medicine composition for treating diabetic foot |
| 07/25/2013 | WO2013082111A3 Geometrically engineered particles and methods for modulating macrophage or immune responses |
| 07/25/2013 | WO2013081563A3 Stable voglibose tablet formulations |
| 07/25/2013 | WO2013063271A4 Artemisinin and berberine compositions and methods of making |
| 07/25/2013 | WO2013024362A3 Cardiovascular therapeutics |
| 07/25/2013 | WO2013003114A8 Esters for treatment of ocular inflammatory conditions |
| 07/25/2013 | WO2012162777A9 Oral pharmaceutical composition comprising a proton pump inhibitor and a prokinetic agent that can be used in excess stomach acid disorders |
| 07/25/2013 | US20130190401 Veterinary dermatologic composition |
| 07/25/2013 | US20130190398 Ophthalmic compositions and methods for treating eyes |
| 07/25/2013 | US20130190354 Pharmaceutical compositions containing a dgat1 inhibitor |
| 07/25/2013 | US20130190341 High bioavailability opioid formulations |
| 07/25/2013 | US20130190337 Solid dosage forms of hiv protease inhibitors |
| 07/25/2013 | US20130190274 Topical drug delivery system with dual carriers |
| 07/25/2013 | US20130189522 Film-forming composition for soft capsules |
| 07/25/2013 | US20130189369 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation |
| 07/25/2013 | US20130189368 Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| 07/25/2013 | US20130189367 Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells |
| 07/25/2013 | US20130189366 Drug delivery systems and methods of use |
| 07/25/2013 | US20130189365 Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| 07/25/2013 | US20130189364 Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections |
| 07/25/2013 | US20130189361 Combination tablet with chewable outer layer |
| 07/25/2013 | US20130189360 Compressed composition |
| 07/25/2013 | US20130189359 Wet Granulation Using a Water Sequestering Agent |
| 07/25/2013 | US20130189358 Saxagliptin pharmaceutical formulations |
| 07/25/2013 | US20130189357 Methods and Delivery Vehicles for Providing Throat Relief |
| 07/25/2013 | US20130189356 Pellet formulation for the treatment of the intestinal tract |
| 07/25/2013 | US20130189355 Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| 07/25/2013 | US20130189353 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 07/25/2013 | US20130189352 Liposome comprising combination of chloroquine and adriamycin and preparation method thereof |
| 07/25/2013 | US20130189351 Lipids suitable for liposomal delivery of protein coding rna |
| 07/25/2013 | US20130189350 Sustained release formulation of a non-steroidal anti-inflammatory drug |
| 07/25/2013 | US20130189349 Sustained-release liposomal anesthetic compositions |
| 07/25/2013 | US20130189348 Sustained release formulation of a non-steroidal anti-inflammatory drug |
| 07/25/2013 | US20130189347 Disease treatment drug |
| 07/25/2013 | US20130189346 Wound dressing |
| 07/25/2013 | US20130189344 Human lubrication gel |
| 07/25/2013 | US20130189343 Transmucosal administration system for a pharmaceutical drug |
| 07/25/2013 | US20130189342 Heterogeneous implantable devices for drug delivery |
| 07/25/2013 | US20130189341 Generation of photoreceptors from human retinal progenitor cells using polycaprolactone substrates |
| 07/25/2013 | US20130189338 Bone fibers having extended length |
| 07/25/2013 | US20130189334 Enhancing properties by the use of nanoparticles |
| 07/25/2013 | US20130189333 Oral product |
| 07/25/2013 | US20130189324 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
| 07/25/2013 | US20130189321 Parental Composition Comprising Microsperes with a Diameter between 10 and 20 Microns |
| 07/25/2013 | US20130189320 Method of preparing a controlled release particle of soy isoflavone with biodegradable polymer using a supercritical fluid extraction of emulsion (sfee) process |
| 07/25/2013 | US20130189319 Methods and compositions for administration of oxybutynin |
| 07/25/2013 | US20130189318 Solid dispersions comprising tacrolimus |
| 07/25/2013 | US20130189316 Nanoemulsion composition containing vitamin k |
| 07/25/2013 | US20130189315 Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same |
| 07/25/2013 | US20130189314 Enteric-coated ht-2157 compositions and methods of their use |
| 07/25/2013 | US20130189304 Preservation of bioactive materials by freeze dried foam |
| 07/25/2013 | US20130189241 Regulated delivery systems for inner ear drug application and uses thereof |
| 07/25/2013 | US20130189196 Foamable Composition |